Medline Survives Tariffs and Delays on Path to US 2025 IPO Record
December 16, 2025, 12:00 PM UTC (Updated 2:46 PM UTC)
Medline Inc. is poised to deliver the year’s largest US initial public offering, despite persistent tariffs and setbacks that have slowed its journey back to public markets. Investors, drawn to the company’s core business model in the medical supply sector, remain confident the flotation will proceed.
Originally backed by a prominent consortium—Blackstone Inc., Carlyle Group Inc., and Hellman & Friedman—who together took a controlling stake in a deal valued at about $34 billion in 2021, Medline is now targeting a raise of up to $5.37 billion in its IPO. If realized, this would crown the year with the biggest US listing at the lower end of the price range and stand as the largest global IPO of the year at the upper end.
But here’s where the story gets complicated: tariffs continue to weigh on the company’s prospects, and the road to market remains thorny. Yet the enthusiasm from investors who believe in Medline’s long-term growth potential signals that the deal could still capture the market’s strongest appetite for a healthcare-focused business.
Controversy often surrounds timing and valuation in IPOs like Medline’s. Some observers question whether the company can sustain demand and pricing amid ongoing tariff-related pressures and broader market volatility. Others argue that Medline’s entrenched position in the supply chain and its scalable business model could help it weather the headwinds and deliver meaningful returns for public investors.
What do you think? Should Medline press ahead with the planned fundraising at these levels, or wait for a more favorable market environment? Share your views in the comments.
